Mizuho Forecasts Strong Price Appreciation for Pediatrix Medical Group (NYSE:MD) Stock

Pediatrix Medical Group (NYSE:MD) had its price objective increased by Mizuho from $13.00 to $15.00 in a research report sent to investors on Monday morning, Benzinga reports. Mizuho currently has a neutral rating on the stock.

Several other brokerages have also recently issued reports on MD. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. Truist Financial increased their target price on Pediatrix Medical Group from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, UBS Group boosted their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and a consensus target price of $16.10.

Pediatrix Medical Group Stock Performance

Shares of MD opened at $16.06 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a market cap of $1.38 billion, a P/E ratio of -5.25, a P/E/G ratio of 2.35 and a beta of 1.55. The business’s 50 day moving average price is $11.89 and its 200-day moving average price is $9.54. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.29 earnings per share. Equities research analysts anticipate that Pediatrix Medical Group will post 1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, CFO C Marc Richards sold 32,562 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $10.08, for a total value of $328,224.96. Following the transaction, the chief financial officer now directly owns 192,785 shares in the company, valued at $1,943,272.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO C Marc Richards sold 32,562 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the transaction, the chief financial officer now owns 192,785 shares in the company, valued at $1,943,272.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,100 shares of company stock worth $701,889. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. nVerses Capital LLC bought a new stake in Pediatrix Medical Group during the second quarter valued at about $31,000. Innealta Capital LLC purchased a new position in shares of Pediatrix Medical Group during the 2nd quarter valued at about $33,000. Nisa Investment Advisors LLC grew its stake in shares of Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares during the period. CWM LLC increased its holdings in Pediatrix Medical Group by 134.0% in the 3rd quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after acquiring an additional 3,681 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Pediatrix Medical Group during the 2nd quarter worth approximately $72,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.